home
about us
member log-in
contact us

PRODUCTS
MUNICIPAL BONDS
INDEX FUNDS
- Total Asset Fund (TAF)
EVENTS
MARKET RESEARCH

Recent Quotes

View Full List

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Arcturus Therapeutics Holdings Inc (NQ:ARCT)

6.570 +0.200 (+3.14%)

Streaming Delayed Price Updated: 11:45 AM EST, Jan 6, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Arcturus Therapeutics Holdings Inc

< Previous 1 2 3 4 5 6 7 8 9

...

11 12 Next >

Arcturus Therapeutics Presents New Clinical Data at 47th Annual European Cystic Fibrosis Conference

June 07, 2024

From Arcturus Therapeutics Holdings Inc.

Via Business Wire

Arcturus Therapeutics' Early Cystic Fibrosis Trial Results Encouraging - Analyst Cautiously Optimistic ↗

May 28, 2024

Arcturus Therapeutics' early Phase 1 results show ARCT-032 is safe and well-tolerated, with promising improvements in lung function.

Via Benzinga

Nvidia, Insmed, Agios Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday ↗

May 28, 2024

Via Benzinga

The Analyst Verdict: Arcturus Therapeutics In The Eyes Of 4 Experts ↗

March 11, 2024

Via Benzinga

Recap: Arcturus Therapeutics Q4 Earnings ↗

March 07, 2024

Via Benzinga

Earnings Preview: Arcturus Therapeutics ↗

March 06, 2024

Via Benzinga

Evaluating NASDAQ:ARCT for Growth Investment Opportunities. ↗

February 27, 2024

High growth, ROE and beating expectations for NASDAQ:ARCT: growth investors may appreciate this.

Via Chartmill

Why Applied DNA Sciences Shares Are Trading Lower By Around 68%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗

May 28, 2024

Via Benzinga

Arcturus Therapeutics Announces Positive Development for Cystic Fibrosis Program

May 28, 2024

From Arcturus Therapeutics Holdings Inc.

Via Business Wire

Is NASDAQ:ARCT suited for growth investing? ↗

February 06, 2024

Is ARCTURUS THERAPEUTICS HOLDIN (NASDAQ:ARCT) suited for growth investing?

Via Chartmill

Achilles Therapeutics Announces Research Collaboration with Arcturus Therapeutics to Explore Second-Generation Personalized mRNA Cancer Vaccines

May 22, 2024

From Achilles Therapeutics PLC

Via GlobeNewswire

Nature Communications Publishes Pivotal Data Demonstrating Efficacy and Tolerability of CSL and Arcturus Therapeutics’ COVID-19 Vaccine

May 20, 2024

From Arcturus Therapeutics

Via Business Wire

Arcturus Therapeutics to Attend Upcoming Investor & Scientific Conferences

May 15, 2024

From Arcturus Therapeutics Holdings Inc.

Via Business Wire

Elon Musk Breaks Ranks With GOP By Praising Genetic Engineering Tech That Helped Fight COVID-19: 'Digital Medicine With Incredible Potential' ↗

May 09, 2024

Elon Musk has come off as a flagbearer of the mRNA technology, which is seen holding out a lot of promise by scientists.

Via Benzinga

ARCT Stock Earnings: Arcturus Therapeutics Beats EPS, Beats Revenue for Q1 2024 ↗

May 08, 2024

ARCT stock results show that Arcturus Therapeutics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.

Via InvestorPlace

Arcturus Therapeutics Announces First Quarter 2024 Financial Update and Pipeline Progress

May 08, 2024

From Arcturus Therapeutics Holdings Inc.

Via Business Wire

Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 8, 2024

April 25, 2024

From Arcturus Therapeutics Holdings Inc.

Via Business Wire

ARCT Stock Earnings: Arcturus Therapeutics Beats EPS, Misses Revenue for Q4 2023 ↗

March 07, 2024

ARCT stock results show that Arcturus Therapeutics beat analyst estimates for earnings per share but missed on revenue for the fourth quarter of 2023.

Via InvestorPlace

Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2023 Financial Update and Pipeline Progress

March 07, 2024

From Arcturus Therapeutics Holdings Inc.

Via Business Wire

7 Under-the-Radar Biotech Stocks Gearing Up for Liftoff ↗

February 26, 2024

Although the health innovation space can be a risky environment, undervalued biotech stocks can take some of the edge off.

Via InvestorPlace

Arcturus Therapeutics to Present at the Barclays 26th Annual Global Healthcare Conference

February 26, 2024

From Arcturus Therapeutics Holdings Inc.

Via Business Wire

Earnings Scheduled For March 7, 2024 ↗

March 07, 2024

Companies Reporting Before The Bell • CI&T (NYSE:CINT) is estimated to report quarterly earnings at $0.06 per share on revenue of $106.08 million.

Via Benzinga

Arcturus Therapeutics Receives Orphan Medicinal Product Designation from the European Commission (EC), for ARCT-032, for the Treatment of Cystic Fibrosis

February 22, 2024

From Arcturus Therapeutics Holdings Inc.

Via Business Wire

Wall Street Favorites: 3 Biotech Stocks With Strong Buy Ratings for February 2024 ↗

February 21, 2024

Biotech stocks are often at the forefront of innovation. These picks are worth considering for your portfolio for their growth potential.

Via InvestorPlace

3 Tech Stocks That Could Be Multibaggers in the Making: February Edition ↗

February 20, 2024

We have researched tech stocks for you and have found these three are likely multibaggers in the making. Considering picking them up today.

Via InvestorPlace

Arcturus Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update on March 7, 2024

February 20, 2024

From Arcturus Therapeutics Holdings Inc.

Via Business Wire

New COVID-19 sa-mRNA Results from CSL and Arcturus Therapeutics Demonstrate Longer Duration of Immunity Compared to Conventional COVID-19 mRNA Vaccine Booster

February 05, 2024

From Arcturus Therapeutics

Via Business Wire

Logitech Posts Q3 Results, Joins Coinbase And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗

January 23, 2024

U.S. stock futures were mostly lower this morning, with the Dow futures falling around 20 points on Tuesday.

Via Benzinga

Topics Stocks

Why the growth investor may take a look at ARCTURUS THERAPEUTICS HOLDIN (NASDAQ:ARCT). ↗

January 16, 2024

ARCTURUS THERAPEUTICS HOLDIN (NASDAQ:ARCT) may be suited for growth investing, we'll explore why in this article.

Via Chartmill

ARCTURUS THERAPEUTICS HOLDIN (NASDAQ:ARCT) showing high EPS and FCF growth while beating expectations ↗

December 26, 2023

Exploring growth characteristics of ARCTURUS THERAPEUTICS HOLDIN (NASDAQ:ARCT).

Via Chartmill

< Previous 1 2 3 4 5 6 7 8 9

...

11 12 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Home
About Us
Products
Municipal Bonds
Index Funds
Seminars & Events
Market Research
Contact Us
Member Section
Privacy Policy
Terms & Conditions
Security Notice
Customer Service

Securities offered through Purshe Kaplan Sterling Investments, member FINRA / SIPC, Headquartered at 80 State Street,
Albany, NY 12207
Purshe Kaplan Sterling Investments and Tamar Securities, LLC are not affiliated companies.
Tamar Securities, LLC is a Registered Investment Adviser. Advisory services are only offered to clients or prospective clients where Tamar Securities, LLC
and its representatives are properly licensed or exempt from licensure. Past performance is no guarantee of future returns. Investing involves risk and possible loss of principal capital.
No advice may be rendered by Tamar Securities, LLC unless a client service agreement is in place.

NOT FDIC INSURED. NOT BANK GUARANTEED. MAY LOSE VALUE, INCLUDING LOSS OF PRINCIPAL. NOT INSURED BY ANY STATE OR FEDERAL AGENCY.
Web development by IBCnet.com